Du Zhenfang相关文献与解析，生知库 | 链接生命科学的每一步

Network pharmacology and experimental validation to elucidate the pharmacological mechanisms of Guben Xiezhuo decoction against renal fibrosis.

通过网络药理学和实验验证，阐明古本泻火汤治疗肾纤维化的药理机制

期刊:Scientific Reports

影响因子:3.9

doi:10.1038/s41598-025-16012-6

Chen Shutao, Liu Yue, Zhu Liwei, Wu Jingyi, Xu Ziyun, Zhang Yingyu, Wei Minggang, Du Zhenfang, Qiang Sheng

发表日期：2025

文献求助收藏

Wnt/β-catenin signaling in the development and therapeutic resistance of non-small cell lung cancer

Wnt/β-catenin信号通路在非小细胞肺癌的发生发展和治疗耐药性中的作用

期刊:Journal of Translational Medicine

影响因子:7.5

doi:10.1186/s12967-024-05380-8

Zhang, Zixu; Westover, David; Tang, Zhantong; Liu, Yue; Sun, Jinghan; Sun, Yunxi; Zhang, Runqing; Wang, Xingyue; Zhou, Shihui; Hesilaiti, Nigaerayi; Xia, Qi; Du, Zhenfang

Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer

针对EGFR突变型非小细胞肺癌患者的结构导向靶向治疗策略

期刊:Biomolecules

影响因子:4.8

doi:10.3390/biom13020210

Du, Zhenfang; Sun, Jinghan; Zhang, Yunkai; Hesilaiti, Nigaerayi; Xia, Qi; Cui, Heqing; Fan, Na; Xu, Xiaofang

Erratum: Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas: Erratum

勘误：p53调控的3p22.2肿瘤抑制基因的表观基因组学特征分析，该基因通过蛋白质对接抑制STAT3磷酸化，并在食管癌和其他癌中经常发生甲基化：勘误

期刊:Theranostics

影响因子:13.3

doi:10.7150/thno.70351

Li, Lili; Xu, Juan; Qiu, Guohua; Ying, Jianming; Du, Zhenfang; Xiang, Tingxiu; Wong, Kai Yau; Srivastava, Gopesh; Zhu, Xiao-Feng; Mok, Tony S; Chan, Anthony Tc; Chan, Francis Kl; Ambinder, Richard F; Tao, Qian

Mechanisms of receptor tyrosine kinase activation in cancer

癌症中受体酪氨酸激酶激活的机制

期刊:Molecular Cancer

影响因子:33.9

doi:10.1186/s12943-018-0782-4

Du, Zhenfang; Lovly, Christine M

The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.

表观遗传修饰因子 CHD5 是一种新型的肾细胞癌肿瘤抑制因子，主要通过启动子 CpG 甲基化而失活

期刊:Oncotarget

影响因子:

doi:10.18632/oncotarget.7822

Du Zhenfang, Li Lili, Huang Xin, Jin Jie, Huang Suming, Zhang Qian, Tao Qian

RSPO4 exerts tumor suppression through antagonizing canonical and non-canonical Wnt signaling

RSPO4通过拮抗经典和非经典Wnt信号通路发挥肿瘤抑制作用

Diverse functions of NLRP3 inflammasome in PANoptosis and diseases

NLRP3炎症小体在PANoptosis和疾病中的多种功能

Network pharmacology and experimental validation to elucidate the pharmacological mechanisms of Guben Xiezhuo decoction against renal fibrosis.

通过网络药理学和实验验证，阐明古本泻火汤治疗肾纤维化的药理机制

Wnt/β-catenin signaling in the development and therapeutic resistance of non-small cell lung cancer

Wnt/β-catenin信号通路在非小细胞肺癌的发生发展和治疗耐药性中的作用

Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer

针对EGFR突变型非小细胞肺癌患者的结构导向靶向治疗策略

Erratum: Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas: Erratum

勘误：p53调控的3p22.2肿瘤抑制基因的表观基因组学特征分析，该基因通过蛋白质对接抑制STAT3磷酸化，并在食管癌和其他癌中经常发生甲基化：勘误

Mechanisms of receptor tyrosine kinase activation in cancer

癌症中受体酪氨酸激酶激活的机制

The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.

表观遗传修饰因子 CHD5 是一种新型的肾细胞癌肿瘤抑制因子，主要通过启动子 CpG 甲基化而失活